Anticoagulation and antiplatelet agent use among patients with von Willebrand disease and cardiac disease

Blood Adv. 2024 May 14;8(9):2244-2247. doi: 10.1182/bloodadvances.2023012348.

Authors

Lauren E Merz^{1

2}, Duaa AbdelHameid³, Dareen M Kanaan⁴, Subrina Farah⁵, Peter Manzo⁴, Nathan T Connell^{1

6}

Affiliations

¹ Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
² Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
³ Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX.
⁴ Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA.
⁵ Department of Data Science, Brigham and Women's Hospital, Boston, MA.
⁶ Harvard Medical School, Boston, MA.

No abstract available

MeSH terms

Aged
Anticoagulants* / therapeutic use
Female
Heart Diseases* / drug therapy
Heart Diseases* / etiology
Humans
Male
Middle Aged
Platelet Aggregation Inhibitors* / therapeutic use
von Willebrand Diseases* / drug therapy